The Salford study recruited a total of 4,233 patients who were taking inhaled corticosteroid (ICS) with or without a long acting beta 2-agonist (LABA) were randomised to receive either FF/VI or to ...

The drug, which combines an inhaled corticosteroid (ICS) with a long-acting beta 2 agonist, was co-developed with Innoviva. Mike Aguiar, CEO of Innoviva, said “We believe the results of this ...

More migraine treatments than ever have become available in recent years, with more on the way. Discover the many options ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Expert Rev Endocrinol Metab. 2013;8(3):247-259. It is unclear to what degree these specific changes in CV parameters and risk factors play in overall clinical outcomes. As earlier outlined, short ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

GnRH agonists are the established treatment of precocious ... 24 h after third injection; 2 h after ninth injection; 14 h after last injection of drugs after decapitation in the morning.

CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Eur. Heart. J. 25(15), 1341–1362 (2004). Brodde OE. β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther.

Cactus Feeders has fed more than 2 million head with the product since 2004. Karr points out in the 15 years Cactus Feeders has researched beta agonists, and the 10 years they have fed beta agonists, ...